PRE - Prenetics stock surges ~45% on FDA nod for genomic profiling test for tumors
- Prenetics Global ( NASDAQ: PRE ) said ACT Genomics received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company's genomic profiling test for solid tumors.
- Prenetics noted that it had recently completed a majority stake acquisition of ACT Genomics.
- Prenetics this is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test.
- "Today’s landmark clearance by the FDA represents a significant advancement in personalized cancer care in Asia and may lead to reimbursement and coverage by private insurers and healthcare systems," said Danny Yeung, chairman of ACT Genomics and CEO of Prenetics.
- PRE +48.92% to $2.77 premarket Jan. 10
For further details see:
Prenetics stock surges ~45% on FDA nod for genomic profiling test for tumors